^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Non Small Cell Lung Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Lancet Oncol
    Title:

    Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

    Excerpt:
    PFS was also significantly longer in patients with EGFR-positive immunohistochemistry who were treated with erlotinib (n=307) compared with EGFR-positive patients given placebo…
    DOI:
    10.1016/S1470-2045(10)70112-1
    Trial ID:
    NCT00556712
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Tarceva and Targretin in Stage I-II Lung Cancer

    Excerpt:
    ...Number of Participants With Change in Expression Level of EGFR.`...
    Trial ID:
    NCT00125372
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

    Excerpt:
    ...Phase I: Response rate`Phase 1: Progression Free Survival`Phase 2: Progression Free Survival`Phase 2: Overall Survival`Phase 2: Correlation between level of EGFR expression on the original tumor tissue and the presence of EGFR mutations in exons 18, 19 and 21 in serum DNA and original tumor tissue with the treatment response and outcome.`...
    Trial ID:
    NCT00707252
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

    Excerpt:
    ...Response assessed using RECIST`Level of EGFR expression...
    Trial ID:
    NCT00042835
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)

    Excerpt:
    ...Neither with EGFR mutation nor c-met expression on Ventana Benchmark instrument(...
    Trial ID:
    NCT02006043
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy

    Excerpt:
    ...Correlation of EGFR expression rate and FISH potentially predictive for response...
    Trial ID:
    NCT00452075
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

    Excerpt:
    ...- Request archival diagnostic tissue for EGFR expression but...
    Trial ID:
    NCT00553800
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response

    Excerpt:
    ...To investigate C-met expression/amplification and EGFR gene mutations in NSCLC patients treated with Erlotinib : C-met expression by IHC C-met amplification by SISH EGFR mutation by real time PCR`The rates of C-met expression/amplification and EGFR gene mutations...
    Trial ID:
    MENTOR
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A Phase II Trial of Erlotinib as first line therapy in Non- Small Cell Lung Cancer over-expressing EGFR

    Excerpt:
    ...Histologically or cytologically proven NSCLC, Stage IIIb/IVImmunocytochemical evidence of EGFR over expression (++ or +++) from diagnostic tissue (e.g. bronchoscopic tumour samples core biopsies, fine needle aspirates-FNA).Life expectancy of at least 12 weeksWorld Health Organisation (WHO) performance status of 0-2 Haematological and biochemical indices within the ranges shown below. ...
    Trial ID:
    2007-001264-72
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Lung Cancer
    Title:

    Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer

    Published date:
    05/22/2020
    Excerpt:
    ...treatment, and survival for 873 patients with stage IV EGFR + NSCLC, diagnosed from 2015 through 2017….Compared with erlotinib, OS was worse for gefitinib users (adjusted hazard ratio, 1.30; 95% confidence interval, 1.02-1.64), predominantly in patients with brain metastasis....In patients with brain metastasis, erlotinib showed superior results compared with gefitinib and was similar to afatinib.
    DOI:
    10.1016/j.cllc.2020.05.019